Technology Networks recently had the pleasure of speaking with Prof. Stephen Schoenberger of La Jolla Institute for Immunology to learn more about his laboratorys work, directed towards achieving a comprehensive mechanistic understanding of the generation and regulation of T-cell responses in the context of infection and cancer development.Schoenberger discusses the concept, promise and challenges of precision immunotherapies, and explains how synthetic biology approaches can be used to develop such therapeutics.
Q: What is the goal of precision immunotherapy, and how does this approach differ to other immunotherapeutic approaches?A: Broadly speaking, immunotherapy involves the application of strategies through which various components of the immune system can be directed to eradicate cancer. To-date, this has involved both leveraging positive signals, such as cytokines that promote growth/effector functionality in specific cellular subsets or antibodies that engage costimulatory pathways, as well as methods of uncoupling inhibitory signalling pathways that otherwise restrain the anti-tumor immune response. Although each of these approaches has had a degree of success in specific settings, their effects are not universal across all cancer types, and often come with an appreciable risk of undesired immune damage to normal tissues. This is perhaps understandable when one unleashes the power of the immune system but does not control its targeting. Precision immunotherapy seeks to address this critical issue of tumor-specific targeting to ensure that the potency of the immune system is directed specifically at the cancer cells while minimizing collateral damage to normal cells. The surest way to achieve that at present is to target features that are specific to the tumor.
Q: How can synthetic biology be leveraged to aid the development of precision immunotherapies?A: I believe that the greatest impact of synthetic biology will be in the development of more powerful and precise therapeutic vaccines. Cancer is a genetic disease, meaning it results from specific gene mutations, that alter cells normal functioning and can give rise to neoantigens. These antigens, encoded by tumor-specific mutated genes, are displayed exclusively on the surface of transformed cells. A key goal of precision immunotherapy is to identify the subset that can serve as neoantigens that are recognized by a patients T cells and then to activate/amplify this response. Synthetic biology, and specifically nanoengineering, offer entirely new possibilities for leveraging the potential of the immune system to mount a powerful and coordinated attack on the tumor that is both achievable on a patient-specific basis and scalable. The challenge now is to understand the components of a rationally-designed synthetic vaccine that can induce the desired therapeutic response from the natural biology of a cancer patients immune system.
Q: Can you please elaborate on your lab's work focused on exploring the mechanistic underpinnings of T-cell responses, both in response to infectious pathogens and during cancer development?A: Im fortunate to have received my training in immunology at a time when the fundamental rules that govern the response of T cells to both infectious pathogens and normal self were first being understood at the cellular and molecular level. Since my post-doctoral training with Prof. Kees Melief at the University of Leiden, Ive sought to apply this emerging knowledge to explore whether the same mutations that define the transformed state in cancer cells could be targets for immune recognition and destruction by CD4+ and CD8+ T cells. To approach this, I first needed to understand how T cells work, and have pursued this goal in the context of experimental models of microbial infection, autoimmunity and cancer for over 20 years. During that time, my lab has made contributions to the understanding of CD4+/CD8+ T cell regulation and have identified some of the genes and pathways that govern this. In parallel, remarkable progress in the field of immunology has produced a body of knowledge that enables an integrated and holistic view of immunity and the parameters that influence the class, magnitude, specificity and regulation of immune responses. The emerging view is that tumors occupy a special niche within the context of immunity. They are clearly different than normal cells because of the mutated proteins they express, and should therefore be recognizable by the immune system, but lack the molecular features of infectious pathogens that are needed to initiate and amplify that response.
Q: Can you talk to us about the concept of a vaccine design for certain types of cancer, and how the work of your lab helps to inform research in this space?A: The work in my lab towards vaccine design has proceeded along two main paths: targeting and delivery. Through the first path, we have pursued methods of identifying which mutations expressed in a tumor represent therapeutically-actionable targets; which mutations can serve as neoantigens, in other words. The advent of rapid and cost-effective genomic sequencing has made the routine identification of expressed mutations in cancer widely possible, and much effort in the field of immuno-oncology has been applied towards determining which of these can be "seen" by the patients immune system, with the overwhelming majority of these taking a predictive computational approach. We have taken a different tack on this, and one based on the assumption that within the cancer patient, the immune system has already mounted a physiological T-cell response to a subset of the expressed mutations that is quantitatively small and therapeutically ineffective, but which can be expanded and empowered through vaccination to eradicate disseminated metastases. The second arm of this effort is focused on methods to improve the specificity, potency and durability of therapeutic vaccine-induced T-cell responses based on an integrated holistic view of the immune system. These efforts involve coordination of the innate and adaptive arms of the immune system, synergies between CD4+ and CD8+ T cells, and evaluating vaccine formulations that are both potent and cost-effective, and which can be produced rapidly enough to meet clinical needs of the patient. There are a number of challenges, but I am convinced that these can be overcome to make the routine and reliable delivery of effective personalized cancer vaccines a clinical reality.
Q: What key challenges remain in pursuing precision immunotherapy?A: Progress in the research space has raised the hypothetical foundations of precision immunotherapy to the level of proof it is now clear that when properly targeted and delivered in sufficient numbers, T cells can eradicate disseminated metastatic cancer. The main challenges, to me, are to understand the mechanistic details underlying successful immunotherapy, to learn the reasons why it works and under what conditions, and then to devise ways in which this information can be applied widely in the setting of community-level oncology. This will require approaches that can quickly move academic discoveries to clinical evaluation and, if successful, to a manufacturing process that is rugged and scalable. This will take new thinking at every level to ensure that scarce resources are directed to not only that which is possible but almost from inception to that which is feasible.
Q: How do you envision your research focus and the technologies that you adopt might evolve over the forthcoming years?A: A central feature of science is that new and often unanticipated technologies can enable huge leaps forward in whats possible, and Ive witnessed this numerous times in my own field in the form of flow cytometry, peptide/MHC tetramers, transgenic mice, laser-confocal microscopy, next-generation sequencing and CRISPR-based genome engineering among others. Although we do not usually focus on their development, Ive tried to stay aware of new technologies and incorporate them into our research when I can understand and appreciate their potential. At heart, however, Im a relatively simple biologist who tends to focus on one question at a time, and at present, that is to understand whether cancer patients possess within their own immune system the capacity to recognize the mutations that define and distinguish cancer and eradicate it based on those differences.
Technologies that will aid in answering that question, and do so for the clinical benefit of cancer patients, will be those that allow insights into the mutations expressed by the cancer and the immune response, earlier, with greater sensitivity and in a less-invasive manner than whats currently possible. A fundamental change in my approach to this scientific problem has been necessarily compelled with the switch from experimental clinical models to our current situation, in which every case we study is a fellow human who has a reasonable expectation to benefit from technological advances to make their treatment more precise, effective and tolerable. Towards that, Im encouraged by advances in the imaging of cancer, liquid biopsy technologies and single-cell sequencing that can allow unprecedented insights into the cancer genome and the T-cell response, and expect that progress in these areas will be crucial to our research goals.
Professor Stephen Schoenberger was speaking with Molly Campbell and Laura Elizabeth Lansdowne, Science Writers, Technology Networks.
Visit link:
Pursuing Precision Immunotherapy for Cancer: Approaches and Challenges - Technology Networks
- Immunology Startup Ouro Sets Out With $120M for Drugs That Reset the Immune System - MedCity News - January 15th, 2025 [January 15th, 2025]
- Scipher Medicine and Atropos Health Partner to Accelerate Precision Medicine and Expand the Immunology Multimodal Network - Business Wire - December 23rd, 2024 [December 23rd, 2024]
- AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition - PMLiVE - December 23rd, 2024 [December 23rd, 2024]
- Sir Gustav Nossal Professor of Immunology to honour giant of Australian science - Walter and Eliza Hall Institute of Medical Research - December 9th, 2024 [December 9th, 2024]
- Research Assistant in Immunology - Surrey, United Kingdom job with UNIVERSITY OF SURREY | 384335 - Times Higher Education - November 28th, 2024 [November 28th, 2024]
- Reflecting on Pioneering organoids and 3D cell cultures for animal and human health - British Society for Immunology | - November 28th, 2024 [November 28th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET - Business Wire - November 20th, 2024 [November 20th, 2024]
- TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development - Business Wire - November 20th, 2024 [November 20th, 2024]
- Discovering Solutions for Long COVID: A T-Cell Immunology Breakthrough - Infection Control Today - November 20th, 2024 [November 20th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET IPH6501 - The Bakersfield Californian - November 20th, 2024 [November 20th, 2024]
- Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of... - November 20th, 2024 [November 20th, 2024]
- What it's like in allergy and immunology: Shadowing Dr. Fraser - American Medical Association - November 12th, 2024 [November 12th, 2024]
- Dr. Naba Sharif Elected President of the New Jersey Allergy Asthma and Immunology Society - Newswire - November 12th, 2024 [November 12th, 2024]
- Department of Microbiology and Immunology Named a National Milestones Program - Stony Brook News - October 26th, 2024 [October 26th, 2024]
- Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - businesswire.com - October 26th, 2024 [October 26th, 2024]
- Remembering immunology educator, researcher Tom McDonald, PhD - University of Nebraska Medical Center - October 13th, 2024 [October 13th, 2024]
- Systems immunology approaches to study T cells in health and disease - Nature.com - October 13th, 2024 [October 13th, 2024]
- Leading the charge to discover answers in immunology - The University of Arizona - October 2nd, 2024 [October 2nd, 2024]
- New mouse models offer valuable window into COVID-19 infection - La Jolla Institute for Immunology - October 2nd, 2024 [October 2nd, 2024]
- Wide-Moat AbbVie Poised for Growth, Driven by Innovation in Immunology Beyond Humira - Morningstar - October 2nd, 2024 [October 2nd, 2024]
- Lilly's immunology unit scores another FDA nod with eczema treatment Ebglyss - FiercePharma - September 23rd, 2024 [September 23rd, 2024]
- Huang Named Head Of Pathology And Immunology - Mirage News - September 15th, 2024 [September 15th, 2024]
- Huang named head of pathology & immunology - Washington University School of Medicine in St. Louis - September 15th, 2024 [September 15th, 2024]
- Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit - Yahoo Finance - September 15th, 2024 [September 15th, 2024]
- Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - StockTitan - September 15th, 2024 [September 15th, 2024]
- UCLA receives $120 million from Alya and Gary Michelson for new California Institute for Immunology and Immunotherapy - UCLA Newsroom - September 2nd, 2024 [September 2nd, 2024]
- Boosting vaccines for the elderly with 'hyperactivators' - Boston Children's Answers - Boston Children's Discoveries - June 27th, 2024 [June 27th, 2024]
- Immunologists Want You to Know These Dust Mite Allergy Facts - Yahoo Lifestyle UK - June 27th, 2024 [June 27th, 2024]
- How Ragon Institute's new building aids its mission Harvard Gazette - Harvard Gazette - June 27th, 2024 [June 27th, 2024]
- Insights into CRS and NPs: Visual and Bibliometric Analysis - Physician's Weekly - June 27th, 2024 [June 27th, 2024]
- Biogen joins immunology wave with $1.15 billion acquisition of HI-Bio - STAT - May 24th, 2024 [May 24th, 2024]
- Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal - Scrip - May 24th, 2024 [May 24th, 2024]
- Biogen Boosts Immunology Portfolio with $1.8 Billion Acquisition of HI-Bio - BioPharm International - May 24th, 2024 [May 24th, 2024]
- Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395 - Yahoo Finance - May 24th, 2024 [May 24th, 2024]
- Biogen to expand immunology and rare disease portfolio with $1.8bn HI-Bio acquisition - PMLiVE - May 24th, 2024 [May 24th, 2024]
- Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress - Business Wire - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B - MM+M Online - May 24th, 2024 [May 24th, 2024]
- COVID-19 Re-Vaccinations Elicit Neutralizing Antibodies Against Future Variants - Technology Networks - May 24th, 2024 [May 24th, 2024]
- HIV Vaccine Candidate Induces Broadly Neutralizing Antibodies in Humans - Technology Networks - May 24th, 2024 [May 24th, 2024]
- Pasteur Fiocruz Center on Immunology and Immunotherapy is inaugurated in Cear - Fiocruz - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal - Marketscreener.com - May 24th, 2024 [May 24th, 2024]
- Fellow Focus in Four: Marat Kribis, MD, Rheumatology, Allergy and Immunology - Yale School of Medicine - April 15th, 2024 [April 15th, 2024]
- Long COVID Can Now Be Detected in the Blood - Technology Networks - April 15th, 2024 [April 15th, 2024]
- Rimjhim Agarwal selected as Major Symposium speaker at the American Association of Immunologists ... - La Jolla Institute for Immunology - March 29th, 2024 [March 29th, 2024]
- Seeking new horizons: Where innovators find opportunities in a fast-changing immunology landscape - IQVIA - March 29th, 2024 [March 29th, 2024]
- Researchers identify new way to inhibit immune cells that drive allergic asthma - EurekAlert - March 29th, 2024 [March 29th, 2024]
- Innovation in Oncology and Cancer Immunology Research - Boehringer Ingelheim - March 29th, 2024 [March 29th, 2024]
- Measles outbreaks show the risk of under-vaccination | News | Harvard T.H. Chan School of Public Health - HSPH News - March 29th, 2024 [March 29th, 2024]
- Immunology-oncology ELISA Kits Market to Witness a Healthy Growth by 2030 - WhaTech - March 29th, 2024 [March 29th, 2024]
- Spring Allergy Season Is Getting Worse. Here's What to Know. - The New York Times - March 29th, 2024 [March 29th, 2024]
- Multiple sclerosis has distinct subtypes, study finds, pointing to different treatments - STAT - March 29th, 2024 [March 29th, 2024]
- Researchers identify viable vaccine targets for hepatitis C infections - News-Medical.Net - March 29th, 2024 [March 29th, 2024]
- Three research projects awarded funding from the Immunology Institute Pilot Project program - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE - Scrip - February 29th, 2024 [February 29th, 2024]
- AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology ... - PR Newswire - February 29th, 2024 [February 29th, 2024]
- Integrating single-cell multi-omics and prior biological knowledge for a functional characterization of the immune system - Nature.com - February 29th, 2024 [February 29th, 2024]
- Renowned immunologist and four-decade UAB researcher Max Cooper, M.D., will deliver this year's Marx Lecture - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Inactivation of TGF- signaling in CAR-T cells | Cellular & Molecular Immunology - Nature.com - February 29th, 2024 [February 29th, 2024]
- Babies use their immune system differently but efficiently | Cornell Chronicle - Cornell Chronicle - February 29th, 2024 [February 29th, 2024]
- Antibody reduces allergic reactions to multiple foods in NIH clinical trial - National Institutes of Health (NIH) (.gov) - February 29th, 2024 [February 29th, 2024]
- Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Theratechnologies announces publication in Frontiers in Immunology on TH1902 - TipRanks.com - TipRanks - February 21st, 2024 [February 21st, 2024]
- Smoking has long-term effects on the immune system - Institut Pasteur - February 21st, 2024 [February 21st, 2024]
- Spring Allergies Attack More Than Just Your Nose - ACAAI Public Website - American College of Allergy Asthma and Immunology - February 21st, 2024 [February 21st, 2024]
- Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Shikhar Mehrotra named co-leader of Cancer Biology and Immunology research program at MUSC Hollings - The Cancer Letter - January 27th, 2024 [January 27th, 2024]
- Gut Microbiome Benefits of Breast Milk Revealed in Mouse Study - Technology Networks - January 27th, 2024 [January 27th, 2024]
- Research on Immunological Diseases Launches with Hungarian Participation - Hungary Today - January 27th, 2024 [January 27th, 2024]
- UCLA to turn former shopping mall into centers for research on immunology and quantum science - The Associated Press - January 8th, 2024 [January 8th, 2024]
- TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration - Business Wire - January 8th, 2024 [January 8th, 2024]
- UCLA to turn former Westside Pavilion into centers for research on immunology and quantum science - KABC-TV - January 8th, 2024 [January 8th, 2024]
- HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases - PR Newswire - January 8th, 2024 [January 8th, 2024]
- Beyond Cytotoxicity: The Importance of T Cell Memory - The Scientist - January 8th, 2024 [January 8th, 2024]
- IKAROS: Unlocking the secrets of the immune system's key player - News-Medical.Net - January 8th, 2024 [January 8th, 2024]
- UCLA to turn former shopping mall into centers for research on immunology and quantum science - The Caledonian-Record - January 8th, 2024 [January 8th, 2024]
- Revolutionizing Vaccine Research: The Power of a New Algorithm - SciTechDaily - December 31st, 2023 [December 31st, 2023]
- Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people ... - Nature.com - December 22nd, 2023 [December 22nd, 2023]
- Two new practice parameters offer recommendations for treating anaphylaxis and atopic dermatitis - News-Medical.Net - December 22nd, 2023 [December 22nd, 2023]
- Physician and Patient (Un)Wellness in Allergy and Immunology During COVID-19 and Beyond: Lessons for the Future - Physician's Weekly - December 22nd, 2023 [December 22nd, 2023]
- Researchers Identify Why Some Cancers Do Not Respond to Immunotherapy - NYU Langone Health - December 22nd, 2023 [December 22nd, 2023]